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Conclusions: This “trumpeting” may also partially explain the observed use of more
Xience stents per lesion compared to Resolute (1.180.45 vs. 1.150.42, p0.02) in the
Resolute All Comers (RAC) trial. The primary cause for secondary stenting in RAC was
“to stabilize target lesion” which includes procedural complications including dissection
or perforations.
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Background: Endothelium dysfunction is among the possible causes related to higher
thrombosis rates after 1st generation DES. Whether the presence of durable polymer or
high anti-proliferative drug dose, or both, can be responsible for this phenomenon is not
clear. In the present study we compared the endothelial function following the implant of
a polymer-free DES with a nanothin-microporous hydroxyapatite surface coating impreg-
nated with a low-dose of Sirolimus (55g) to a BMS equivalent coated with a
hydroxyapatite surface (Vestacor stent).
Methods: The Vestasync II is a randomized, double-blinded trial with 20 pts (10 in each
group) with de novo lesions in native coronary arteries of 3.0-3.5mm diameter and 
14mm in length. The primary goal was to compare the vasomotricity after implantation
of stents with the same platform, with and without drug elution. Endothelial function was
assessed with atrial pacemaker stimulation (20 ppm over basal cardiac frequency until
reach 150 ppm) and the lumen diameter was measured at 5 mm of proximal and distal
stent edges and in a control segment, in different stages (at rest, at successive phases of
stimulli and after nitroglycerin I.C infusion).
Results: As shown in the figure, there was a negative variation in luminal diameter
between basal and maximum stimulli at proximal (10%) and distal (8%) edges of both
groups. Among control segments this variation was less than 3%, an acceptable variation
of QCA method.
Conclusions: The elution of sirolimus does not seem to interfere in endotelial function
8 months after polymer-free hydroxiapatite coating stent implantation.
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Background: Percutaneous intervention (PCI) for degenerated saphenous vein graft
(SVG) lesions are well known for high rates of no-reflow, restenosis (ISR) and stent
thrombosis. Covered stents have been tried in an aim to trap the debris to minimize
no-reflow and ISR. Two types of covered stents have been used for SVG lesions:
pericardium covered stent (PCS) & polytetrafluroethylene (PTFE) covered stent. We
present our long-term follow-up data following the use of both types of covered stents in
our practice.
Methods: Between 1997 and 2004, 52 patients (mean age: 67.14 years) with 65 lesions
in SVG were treated with PTFE covered stents as a part of multicenter trial (RECOV-
ERS). Between 2003 and 2007, 33 patients (mean age: 67.78 years) with 48 SVG lesions
were treated with pericardium-covered stents covered stents as a part of multicenter trial
(SLEEVE II).
Results: All case had TIMI3 flow post PCI and there were no immediate post-procedural
complications. There were no significant differences in the baseline characteristics except
that mean length of PCS were significantly longer than PTFE covered stents (32.3 mm vs
25.1 mm, p0.001). At 5-year follow-up, the rates of TLR was [PTFE: 12 (18.5%), PCS:
13 (27%) p0.17], TVR was [PTFE: 14 (21.5%), PCS: 16 (33%) p0.07]. During the
5-year follow-up period, 8 patients (15%) in the PTFE group and 2 patients (6%) in the
PCS group had died; p0.33. The MACE defined as death, MI, clinically driven TVR
occurred in 34 of 52 PTFE patients (63%) vs. 18 of 33 PCS patients (54.5%); p0.2.
There were two reported cases of definite very late stent thrombosis in the PCS group, but
none in the PTFE group.
Conclusions: The 5 year follow-up data shows no significant differences in the clinical
endpoints between the two covered stents, although numerically it was slightly worse in
the PCS group. The rates of TLR and TVR are not discouraging in either stents given the
complexity of SVG lesions. Considering the complexity of the lesions treated and the
absence of no-reflow, covered stents may provide additional protection. Since there are no
very long-term follow-up with other stents in SVG, we cannot compare these results with
the traditional stents.
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Background: In this study, we investigated the safety of ambulatory percutaneous
coronary intervention (PCI) in high-risk patients according to age, creatinine, ejection
fraction (ACEF) scores.
Methods: The ambulatory PCI group consisted of all consecutive PCI with same-day
discharges at Mount Sinai Hospital from January 1, 2003 to March 31, 2011 who had
follow-up data. The overnight group consisted of all PCI outpatients in 2004 who were
then hospitalized for at least one night. Patients were stratified into two groups based on
ACEF score: low (1.100) and high (1.100). The primary endpoint was a 30-day major
adverse cardiac events (MACE: readmission, all-cause death, and myocardial infarction
(MI).
Results: Out of 4932 patients, 3216 or 65.2% were in the ambulatory group and the rest
(1716) were in the control group. The average age was 61.5 years and were no significant
differences in baseline characteristics. Overall 30-day MACE occurred in similar
frequency in both groups (Table), in high and low ACEF scores.
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Overnight
(reference) Ambulatory
Hazard Ratio (95%
CI)
p
value
no./total no.
(%)
no./total no.
(%)
Low ACEF
MACE 7/618 (1.1) 18/2214 (0.8) 0.716 (0.299 – 1.714) 0.453
Readmission 4/618 (0.6) 16/2214 (0.7)
All-cause
Death
1/618 (0.2) 0/2214 (0)
MI 4/618 (0.6) 3/2214 (0.1)
High ACEF
MACE 35/1098 (3.2) 22/1002 (2.2) 0.683 (0.401 – 1.165) 0.162
Readmission 14/1098 (1.3) 18/1002 (1.8)
All-cause
Death
20/1098 (1.8) 4/1002 (0.4)
MI 4/1098 (0.4) 1/1002 (0.1)
ACEF score: age/left ventricular ejection fraction 	 1 (if creatinine 2 mg/dl).
Conclusions: In this single-center registry, patients who underwent ambulatory PCI had
no worse outcomes than those who stayed at least one night, at high and low ACEF
scores.
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Background: The aim of this study was to evaluate the frequency, predictors and the
clinical outcome of stent thrombosis after DES implantation and bare metal stent (BMS)
implantation in Asian races.
Methods: A total of 14,577 consecutive patients who underwent successful DES
implantation (8,809 patients, 62% of the lesion with Sirolimus-eluting stent: SES, 38% of
the lesion with Paclitaxel-eluting stent: PES) and BMS implantation (5,768 patients) were
included in this study. We evaluate the frequency, predictor of stent thrombosis.
Results: At a mean follow-up of 78.529.9 months in DES and 81.826.4 months in
BMS. The cumulative incidence of stent thrombosis were subacute stent thrombosis
(SAT): 0.5% with DES and 0.6% with BMS, late stent thrombosis (LAST): 0.18% with
DES and 0.1% with BMS, very late stent thrombosis (VLAST): 0.18% per year with DES
and no BMS. Independent predictors of stent thrombosis are bifurcation lesion (OR1.90,
95% CI: 1.83 to 24.24, p0.01) and ejection fraction (OR0.90, 95% CI: 0.86 to 0.94,
p0.03). Only 0.2 % of the patients were died because of the myocardial infarction after
stent thrombosis in both groups.
Conclusions: The incidence of stent thrombosis in Asian races is relatively low (0.5 %
with DES and 0.6% with BMS of SAT, 0.18% increase per year with DES of late stent
thrombosis) at mean follow-up to 7 years. Particular attention will need to be directed to
this complication when the patients have bifurcation lesions or low ejection fraction.
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Background: Aims: To evaluate safety and effectiveness of the Elixir DESyneTM
Novolimus-Eluting Coronary Stent System (CSS) compared to the Endeavor
Zotarolimus-Eluting CSS through assessment of clinical, angiographic, and IVUS
endpoints.
Methods: 210 patients were randomized 2:1 either to the DESyne CSS loaded with 5mcg
per mm of stent length of Novolimus, a sirolimus metabolite, eluted via a durable
methacrylate polymer, or to the Endeavor CSS loaded with 10mcg per mm of stent length
of Zotarolimus eluted via a durable phosphoryl choline polymer. All patients were
analyzed for the primary endpoint of late lumen loss (LLL) assessed by QCA at 9 months.
All patients also underwent evaluation for secondary endpoints which included a
Device-orientated Composite Endpoint (DoCE) defined as: cardiac death, MI not clearly
attributable to a non-intervention vessel, and clinically-indicated target lesion revascular-
ization (TLR); clinically-indicated Target Vessel Revascularization (TVR); and stent
thrombosis all evaluated at 1, 6, 9, and 12 months and annually through 5 years. Stents
were also assessed for angiographic endpoints at 9 months including: in-stent and
in-segment LLL. A subset of patients underwent IVUS evaluation including percent
neointimal obstruction at 9 months. The study met the non-inferiority endpoint and also
demonstrated superiority of the DESyne CSS as compared to control.
Results: Table 1 summarizes 9-month angiographic and IVUS results and clinical results
through 2 years which trend lower for the DESyne stent.
Table 1: 9-month Angiographic, IVUS and Clinical Results
DESyne Endeavor p-value
Angiographic Results
Baseline RVD (post-
procedure)
2.84 0.43 2.91 0.38 0.2
9-month angiographic/IVUS
In-stent LLL 0.11 0.32 0.63 0.42  0.001
% neointimal volume 4.5 5.1 20.9 11.3 0.001
Clinical Results
12-month DoCE (%) 4.3 7.0 0.51
Clinically-indicated TLR 1.4 5.6 0.18
24-month DoCE (%) 4.3 9.0 0.14
Clinically-indicated TLR 1.4 7.0 0.045
Conclusions: The study met the non-inferiority endpoint and also demonstrated
superiority of the DESyne CSS as compared to control. Clinical results through 3 years
and a review of angiographic and IVUS results will be presented.
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Background: Drug eluting stents (DES) have been shown to significantly decrease
restenosis with subsequent need for lesion and/or vessel revascularization when compared
with bare metal stents (BMS) in selected patient groups in both randomized controlled
trials and in observational registries. If their use in all-comers is also associated with a
survival benefit over a longer follow-up is controversial.
Methods: Retrospective analysis of the MIDAS registry for patients who underwent PCI
with BMS between January 1 1997-December 31 1998 (pre DES era, group 1; N
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